Order Article Reprints

Makino T, Sakurai T, Takamatsu S, Nakagawa R, Kamijima T, Kano H, Naito R, Iwamoto H, Yaegashi H, Shigehara K, et al. Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer. Cancers. 2025; 17(19):3151. https://doi.org/10.3390/cancers17193151

Makino, Tomoyuki, Takayuki Sakurai, Shigeyuki Takamatsu, Ryunosuke Nakagawa, Taiki Kamijima, Hiroshi Kano, Renato Naito, Hiroaki Iwamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, and et al. 2025. "Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer" Cancers 17, no. 19: 3151. https://doi.org/10.3390/cancers17193151

Makino, T., Sakurai, T., Takamatsu, S., Nakagawa, R., Kamijima, T., Kano, H., Naito, R., Iwamoto, H., Yaegashi, H., Shigehara, K., Nohara, T., Izumi, K., & Mizokami, A. (2025). Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer. Cancers, 17(19), 3151. https://doi.org/10.3390/cancers17193151